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Case RepoRt
Rh is a complex blood group system with diverse genotypes that 
may encode weak and partial D variants. Standard serologic 
analysis may identify clinically significant D variants as D+; 
nevertheless, individuals with these D variants should be 
managed as D– patients to prevent antibody formation to absent 
D epitopes. Variant identification is necessary during pregnancy 
to allow for timely and appropriate Rh immune globulin (RhIG) 
prophylaxis for hemolytic disease of the fetus and newborn 
(HDFN) as D alloimmunization can occur with some D variants. 
Here, we describe two cases of the RHD*DAU5 allele associated 
with maternal alloanti-D in patients of African ancestry. Two 
obstetric patients were initially serologically classified as D+ with 
negative antibody detection tests on routine prenatal testing. 
Repeat testing at delivery identified anti-D in both patients 
with no history of RhIG administration or transfusion. DNA 
sequencing revealed that both patients possessed the RHD*DAU5 
allele. Cord blood testing on both infants revealed positive direct 
antiglobulin test (DAT) results with anti-D eluted from the red 
blood cells (RBCs) of one of the infants. Despite the positive DAT, 
neither infant experienced anemia or hyperbilirubinemia. We 
document two cases of pregnant women whose RBCs expressed a 
partial D variant and were classified as D+ on the basis of standard 
serologic testing, resulting in subsequent failure to provide 
RhIG prophylaxis. Both cases were associated with alloanti-D 
formation but without significant HDFN. To our knowledge, these 
are the first reported cases of maternal alloanti-D associated 
with the RHD*DAU5 partial D variant. Immunohematology 
2017;33:60–63.
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The Rh blood group system is the most complex and 
polymorphic blood group system; after ABO, it is the most 
clinically significant system in transfusion medicine. This 
complexity is primarily due to the Rh system being encoded 
by two homologous genes, RHD and RHCE, whose close 
proximity allows for conversion to occur between the two 
genes and the subsequent creation of polymorphic proteins 
that are responsible for the plethora of variants observed in 
the Rh system.1
The Rh system contains several highly immunogenic 
antigens. The D antigen in particular provokes antibody 
production in up to 80 percent of D– volunteers transfused 
with D+ blood.2 However, more recent retrospective analyses 
of D– patients who received D+ red blood cells (RBCs) 
have shown lower rates of antibody formation.3,4 D is also 
a significant cause of hemolytic disease of the fetus and 
newborn (HDFN), in which D– women with a D+ fetus may 
be alloimmunized during pregnancy or at delivery. Maternal 
alloimmunization and subsequent HDFN can be prevented in 
the vast majority of women with timely Rh immune globulin 
(RhIG) prophylaxis during pregnancy and after delivery. For 
this reason, the appropriate assignment of D antigen status is 
required for proper selection of blood products and perinatal 
management.
Although the majority of individuals can be correctly 
classified as D+ or D– using routine serologic methods, there 
are D variants that differ from wild-type D that create a gray 
area between these two categories. More than 460 RHD alleles 
have been identified with mutations that result in qualitative 
or quantitative changes in D expression.5 These variations in D 
are broadly, but somewhat artificially, categorized on the basis 
of serologic studies as weak D and partial D phenotypes.
Weak D variants involve changes in the D protein where at 
least one amino acid substitution occurs in the transmembrane 
or intracellular portions of the protein.6 By serologic definition, 
a weak D will give no or weak (≤2+) reactivity with immediate 
spin testing and will show stronger agglutination using an 
indirect antiglobulin test for detection. Prevalence of weak 
D varies by race and ethnicity, and current data suggest that 
individuals with the most common weak D types (types 1, 
2, and 3), which make up the majority of weak D individuals 
found in Europeans,7 are not at risk of alloimmunization by 
D.8 These patients could safely receive D+ blood components 
and would not require RhIG prophylaxis. Unfortunately, the 
identification of patients with exceptional weak D types who 
are susceptible to D alloimmunization is not through serologic 
testing, but only through molecular analysis of the RHD gene.
The term “partial D” has been used to describe qualitative 
variants where amino acid substitutions in the extracellular 
portion of the D protein, or hybrid alleles, result in altered or 
missing epitope expression.6 This group can be very difficult 
to characterize serologically because of extensive variability 
in testing with different anti-D reagents. Consequently, 
RBCs with partial D variants may react strongly with initial 
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testing and be identified as D+, resulting in the individual not 
receiving RhIG prophylaxis during pregnancy or receiving 
D+ RBC transfusions. The frequency of anti-D formation 
occurring in partial D variants under these circumstances 
is not known. There are multiple case reports of obstetric 
patients with a partial D genotype who have formed anti-D 
as a complication of their pregnancy and have had infants 
demonstrating HDFN.9,10 Despite the potential for severe 
HDFN in these infants, the clinical manifestations have been 
mild in the majority of cases.11
Partial D variants vary with race and ethnicity. Current 
serologic D typing strategies in North America and the UK 
are based on detecting partial D phenotypes more commonly 
found in white populations.8 For example, licensed anti-D 
reagents are required to react as D– in the setting of a partial 
DVI variant, which is the most common clinically significant 
partial D in this group. In black populations, the occurrence 
of partial D variants is more frequent, however, as is the 
frequency of anti-D in pregnancies with D+ mothers.12
The DAU allele cluster has been described in individuals 
with African ethnicity,13 and several DAU variants have 
been shown to have variable reactivity when tested with 
common commercially available anti-D reagents.14 DAU 
is a phylogenetically related cluster of alleles with DAU0 
postulated as the primordial allele. The DAU5 allele is defined 
by a mutation (F223V, E233Q, T379M) in RHD in exons 5 and 
8, resulting in recombination of DAU0 and DVI. The DAU5 
partial D allele has not been associated with anti-D resulting 
in HDFN through October 2016.15
In this case report, we describe two obstetric patients 
whose RBCs with a partial D variant were classified as 
D+ during standard prenatal serologic testing resulting 
in subsequent failure to provide RhIG prophylaxis and 
subsequent development of alloanti-D at time of delivery but 
without HDFN.
Case Report
Patient A, a 34-year-old woman (gravis 6, para 2), who 
had emigrated from the Congo, had routine prenatal serologic 
testing at 13 weeks’ gestation completed at a perinatal testing 
laboratory. Testing for D included monoclonal blend Series 
4 and Series 5 anti-D reagents (ImmucorGamma, Norcross, 
GA) on the Galileo Neo automated solid-phase testing platform 
(Immucor). Antibody screening was also performed on the 
Galileo Neo platform using Immucor 2 Cell Capture-R Ready 
Screen. All testing was completed in accordance with the 
manufacturer’s instructions. Patient A’s blood typed as group 
A, D+ (4+ reactivity with both Series 4 and Series 5 anti-D), 
and the antibody detection test was negative. No prior testing 
results were on record for this patient. The pregnancy was 
uneventful, with normal ultrasounds reported at 14, 21, and 
32 weeks’ gestation.
The patient was admitted to the hospital at 40 weeks’ 
gestation in labor, and repeat serologic testing was performed 
at that time. In-hospital testing was performed on the Galileo 
Echo platform (Immucor) with Series 4 and 5 anti-D reagents. 
Her blood type was confirmed as group A, D+, with 4+ 
reactivity with both Series 4 and Series 5 anti-D reagents and 
3+ reactivity with manual tube D testing with Series 5 anti-D. 
Her antibody detection test, also performed on the Galileo 
Echo using 2 Cell Capture-R Ready Screen (ImmucorGamma), 
was positive (3+ reactivity in both cells) with subsequent 
identification of the antibody as anti-D. The direct antiglobulin 
test (DAT) on the patient’s RBCs was negative. There was no 
record of RhIG administration or transfusion for the patient.
This specimen was tested at a reference laboratory with 
single nucleotide polymorphism (SNP) array analysis and 
subsequent DNA sequencing. Molecular analysis included 
genotyping/SNP analysis performed on the ID Core XT 
(Progenika-Grifols, Derio, Spain). Sanger sequencing was 
performed by use of the following: Progenika-Grifols (Medford, 
MA) using genomic DNA extracted from EDTA-whole blood, 
specific primers to PCR-amplify the 10 RHD exons and 
flanking introns, a 3730 DNA Analyzer (Applied Biosystems, 
Foster City, CA) to resolve the extension products by capillary 
electrophoresis, and SeqScape software (Applied Biosystems) 
to analyze data by comparison with the National Center 
for Biotechnology Information (NCBI) reference sequence. 
Genomic DNA sequencing detected the presence of the silenced 
RHD*Pseudogene and a partial D variant RHD*DAU5. The 
patient’s genotyping results on the ID CoreXT for the other Rh 
antigens predicted the RBCs to be C−, c+, E−, and e+, and a 
marker for r′S was not detected.
This patient delivered a healthy girl with APGAR scores 
of 7 and 9 at 1 and 5 minutes, respectively. In-hospital testing 
showed the infant’s cord blood type was group A, D+ with 
DAT reactivity of 1+. An eluate of the cord RBCs contained 
anti-D. The newborn’s plasma bilirubin levels over the next 2 
days ranged from 102 to 151 μmol/L (normal: <200 μmol/L), 
thus prophylactic phototherapy was not required.
Patient B, a 31-year-old woman (gravis 3, para 1) originally 
from West Africa, had routine prenatal testing at 12 weeks’ 
gestation also at the same perinatal testing laboratory. Her 
blood type was group O, D+ (4+ reactivity with Series 4 and 
Series 5 anti-D), and her antibody detection test was negative, 
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consistent with historical records from previous testing in 
2010. Her ultrasounds at 12 and 20 weeks’ gestation were 
normal, and her pregnancy progressed without complication. 
Repeat serologic testing was performed in-hospital predelivery 
at 38 weeks’ gestation when the patient had a caesarian section 
for partial placental abruption. Her blood type was confirmed 
as group O, D+ (4+ reactivity with Series 4, 3+ with Series 5 
anti-D). The patient’s antibody detection test was positive (3+ 
reactivity in two screening cells) with antibody identification 
confirming anti-D. DAT was negative. There was no record of 
RhIG administration or blood transfusion for the patient. This 
maternal specimen was also forwarded for molecular analysis. 
Genomic DNA sequencing detected the presence of a hybrid 
RHD*DIIIa-CE(4-7)-D and a partial RHD*DAU5 allele. The 
patient’s genotyping results on the ID CoreXT for the other Rh 
antigens predicted her RBCs to be c+, E−, e+, with the hybrid 
RHD*DIIIa-CE(4-7)-D encoding variant (partial) C antigen 
expression. The patient’s phenotype was confirmed as C+ 
serologically.
The patient delivered a healthy boy with APGAR scores 
of 9, 10, and 10 at 1, 5, and 10 minutes, respectively. Cord 
specimen testing showed blood group O, D+. DAT was positive 
with weak reactivity, and a subsequent eluate performed on 
cord RBCs was negative. The infant had a transcutaneous 
bilirubin of 147 μmol/L after 24 hours and was discharged 
home without prophylactic phototherapy.
Discussion
Here, we have described two cases of the partial D variant 
DAU5 associated with maternal anti-D in unrelated African 
patients. One mother’s RHD genotype was RHD*Pseudogene/
RHD*DAU5 and the RHD genotype of the other mother 
was RHD*DAU5/RHD*DIIIa-CE(4-7)-D. In both cases, the 
patients were classified as D+ on the basis of concordant strong 
reactivity with two different anti-D reagents. As a result, 
neither mother received RhIG, and both were subsequently 
alloimmunized for D during their pregnancies.
These cases emphasize the importance of being able to 
recognize and identify weak and partial D phenotypes that 
place women of child-bearing potential at risk of forming 
alloanti-D so that subsequent RhIG prophylaxis can be 
provided as well as avoiding transfusion of D+ RBCs.
To avoid this complication, it has been recommended to 
test samples from obstetric patients and potential transfusion 
recipients with two specifically selected monoclonal anti-D 
reagents, that have dissimilar specificities, in an attempt to 
increase the likelihood of identifying variant D expression 
and to potentially identify those in which genotyping may be 
useful.16 The cases we describe did not exhibit the serologic 
discrepancies in D typing that would suggest the presence 
of a D variant, a phenomenon that has been reported 
previously.17 The epitopes altered by the mutation remained 
fully serologically reactive with standard commercial reagents 
used on both automated and manual testing platforms. These 
cases may represent variations in the particular source and 
specificity of antisera, resulting in failure to detect this variant 
antigen.
Fortunately, neither infant in the reported cases 
experienced significant hyperbilirubinemia. The infants did 
not develop anemia nor require phototherapy, and both were 
discharged from the hospital without an extended stay.
Obstetric patients with a partial D phenotype are known 
to have the potential to form anti-D during pregnancy, and 
their infants are at risk for HDFN. Despite the potential for 
severe HDFN due to anti-D, the clinical manifestations in 
patients with partial D have been mild in the majority of cases 
except for those in mothers with DVI variants.11
The reason for partial D variants to be associated with 
a lesser degree of morbidity when compared with HDFN in 
D– individuals with alloanti-D is unknown. One hypothesis 
proposes that because D variants do express numerous 
epitopes of the D antigen, the associated anti-D may not 
have a broad specificity and hence has diminished hemolytic 
potential compared with anti-D in a D– individual.18
These two cases highlight the limitations of routine 
serologic testing to detect some partial D variants. A 
commentary by Sandler et al.19 of the AABB–College of 
American Pathologists (CAP) Working Group proposed 
selective integration of RHD genotyping in routine obstetric 
and pre-transfusion testing to improve the accuracy of D 
typing results, to reduce unnecessary RhIG administration 
in women with serologic weak D phenotypes, and to overall 
decrease transfusion of scarce D– RBCs to patients with 
weak D phenotypes. The AABB-CAP Working Group did not 
address management of partial D phenotypes, except in the 
management of discordant D typing results, in which case 
they recommend RHD genotyping.19 The incorporation of 
genotyping into prenatal testing may offer a solution, although 
the significant cost of this methodology limits use in routine 
testing. The implementation of genotyping of D+ women of 
childbearing age who are of African descent may offer a more 
feasible solution to this issue.
To our knowledge, these are the first reported cases of 
maternal alloanti-D associated with the RHD*DAU5 partial 
D variant. Neither infant experienced clinically significant 
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anemia nor hyperbilirubinemia although the RBCs of both 
infants reacted in the DAT.
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